BFA
ORKA

BlackRock Fund Advisors’s Oruka Therapeutics ORKA Stock Holding History

BlackRock Fund Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$43K Hold
69
– – ﹤0.01% 3794
2016
Q3 		$42K Buy
69
+9
+15% +$5.8K ﹤0.01% 3815
2016
Q2 		$38K Buy
60
+57
+1,900% +$42.2K ﹤0.01% 3860
2016
Q1 		$3K Hold
3
– – ﹤0.01% 4194
2015
Q4 		$3K Buy
+3
New +$3.4K ﹤0.01% 4246

Other funds holding ORKA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACP
Aveo Capital Partners Englewood, Colorado $601M AUM 5.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock Fund Advisors's ORKA Position: Q4 2016 in Review

BlackRock Fund Advisors held its Oruka Therapeutics (ORKA) position steady in Q4 2016 at 69 shares worth $43K. The position accounts for ﹤0.01% of the portfolio, ranked #3794.

BlackRock Fund Advisors first reported a position in ORKA in Q4 2015 and has held it in 5 quarters since. 16 funds tracked by Wall St. Rank hold ORKA as of Q4 2016.

  • BlackRock Fund Advisors held 69 shares of Oruka Therapeutics worth $43K as of Q4 2016.
  • BlackRock Fund Advisors left its Oruka Therapeutics share count unchanged in Q4 2016.
  • Oruka Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3794 holding.
  • BlackRock Fund Advisors first reported a position in Oruka Therapeutics in Q4 2015 and has held it in 5 quarters since.
  • 16 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.